Targets for current pharmacologic therapy in cholesterol gallstone disease

Gastroenterology Clinics of North America

Volumn 39, Issue 2, 2010, Pages 245-264

  Di Ciaula, Agostino ^a   Wang, David Q H ^b   Wang, Helen H ^c   Bonfrate, Leonilde ^d   Portincasa, Piero ^d  

^a Division of Internal Medicine   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Bile salts; Cholesterol absorption; Ezetimibe; Gallbladder; Nuclear receptors; Statins

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ANALGESIC AGENT; BILE ACID CONJUGATE; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; KETOROLAC; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PETHIDINE; PLACEBO; SCOPOLAMINE; TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID; AZETIDINE DERIVATIVE; CHOLESTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; BILE SECRETION; BILIARY COLIC; CHOLECYSTECTOMY; CHOLECYSTOGRAPHY; CHOLESTEROL METABOLISM; CHOLESTEROL STONE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DIARRHEA; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GALLSTONE DISSOLUTION; GALLSTONE FORMATION; HUMAN; INTESTINE ABSORPTION; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; DRUG EFFECTS; GALLSTONES; METABOLISM; TREATMENT OUTCOME;

AZETIDINES; CHOLESTEROL; CHOLINERGIC ANTAGONISTS; GALLSTONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; TREATMENT OUTCOME; EZETIMIBE;

EID: 85003340018     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.02.005     Document Type: Review

References (175)

1. Portincasa P., Moschetta A., Palasciano G. Cholesterol gallstone disease. Lancet 2006, 368(9531):230-239.
2. Wang D.Q., Afdhal N.H. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep 2004, 6(2):140-150.
3. Everhart J.E., Khare M., Hill M., et al. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999, 117(3):632-639.
4. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122(5):1500-1511.
5. Action plan for liver disease research 2004, Liver Disease Subcommittee of the Digestive Disease Interagency Coordinating Committee, NIH, Bethesda (MD), p. 145-50.
6. Diehl A.K. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am 1991, 20(1):1-19.
7. Attili A.F., Carulli N., Roda E., et al. Epidemiology of gallstone disease in Italy: prevalence data of the multicenter italian study on cholelithiasis (M.I.C.O.L. Am J Epidemiol 1995, 141:158-165.
8. Attili A.F., Capocaccia R., Carulli N., et al. Factors associated with gallstone disease in the MICOL experience. Hepatology 1997, 26:809-818.
9. Sherlock S., Dooley J. Diseases of the liver and biliary system 2002, Blackwell Science, Oxford (UK).
10. Grundy S.M., Barnett J.P. Metabolic and health complications of obesity. Dis Mon 1990, 36:641-731.
11. Grundy S.M. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 2005, 25(11):2243-2244.
12. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
13. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365(9468):1415-1428.
14. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004, 80(1):38-44.
15. Ford E.S., Giles W.H., Mokdad A.H. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004, 27(10):2444-2449.
16. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005, 28(11):2745-2749.
17. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Dietary protein and the risk of cholecystectomy in a cohort of US women: the Nurses' Health Study. Am J Epidemiol 2004, 160(1):11-18.
18. Tsai C.J., Leitzmann M.F., Hu F.B., et al. Frequent nut consumption and decreased risk of cholecystectomy in women. Am J Clin Nutr 2004, 80(1):76-81.
19. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Fruit and vegetable consumption and risk of cholecystectomy in women. Am J Med 2006, 119(9):760-767.
20. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Long-term intake of dietary fiber and decreased risk of cholecystectomy in women. Am J Gastroenterol 2004, 99(7):1364-1370.
21. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Long-term intake of trans-fatty acids and risk of gallstone disease in men. Arch Intern Med 2005, 165(9):1011-1015.
22. Leitzmann M.F., Rimm E.B., Willett W.C., et al. Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med 1999, 341(11):777-784.
23. Tsai C.J., Leitzmann M.F., Willett W.C., et al. The effect of long-term intake of cis unsaturated fats on the risk for gallstone disease in men: a prospective cohort study. Ann Intern Med 2004, 141(7):514-522.
24. Leitzmann M.F., Giovannucci E.L., Rimm E.B., et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998, 128(6):417-425.
25. Shaffer E.A. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006, 20(6):981-996.
26. Zhu X., Zhang S., Huang Z. Zhonghua Wai Ke Za Zhi 1995, 33(11):652-658. [in Chinese].
27. Huang Y.C., Zhang X.W., Yang R.X. Changes in cholelithiasis in Tianjin in the past 30 years. Chin Med J (Engl) 1984, 97(2):133-135.
28. Sun H., Tang H., Jiang S., et al. Gender and metabolic differences of gallstone diseases. World J Gastroenterol 2009, 15(15):1886-1891.
29. Nakayama F., Miyake H. Changing state of gallstone disease in Japan. Composition of the stones and treatment of the condition. Am J Surg 1970, 120(6):794-799.
30. Nagase M., Tanimura H., Setoyama M., et al. Present features of gallstones in Japan. A collective review of 2,144 cases. Am J Surg 1978, 135(6):788-790.
31. Wang H.H., Portincasa P., Wang D.Q. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci 2008, 13:401-423.
32. Portincasa P., Di Ciaula A., Wang H.H., et al. Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology 2008, 47(6):2112-2126.
33. Wittenburg H., Lammert F. Genetic predisposition to gallbladder stones. Semin Liver Dis 2007, 27(1):109-121.
34. Wang D.Q.H., Zhang L., Wang H.H. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim Biophys Acta 2005, 1733(1):90-99.
35. Lammert F., Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol 2005, 2(9):423-433.
36. Portincasa P., Moschetta A., Puglisi F., et al. Medical treatment of gallstone disease. Biliary lithiasis. Basic science, current diagnosis and management 2008, 149-157. Springer Italia S.r.l, Milano (Italy). G. Borzellino, C. Cordiano (Eds.).
37. Lammert F., Miquel J.F. Gallstone disease: from genes to evidence-based therapy. J Hepatol 2008, 48(Suppl 1):S124-S135.
38. Kovacs P., Kress R., Rocha J., et al. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol 2008, 48(1):116-124.
39. Van Mil S.W., Milona A., Dixon P.H., et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007, 133(2):507-516.
40. Portincasa P., Moschetta A., Petruzzelli M., et al. Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Pract Res Clin Gastroenterol 2006, 20(6):1017-1029.
41. Diehl A.K., Sugarek N.J., Todd K.H. Clinical evaluation for gallstone disease: usefulness of symptoms and signs in diagnosis. Am J Med 1990, 89(1):29-33.
42. Paumgartner G., Carr-Locke D.L., Roda E., et al. Biliary stones: non-surgical therapeutic approach. Gastroenterol Int 1988, 1(1):17-24.
43. Jorgensen T. Abdominal symptoms and gallstone disease: an epidemiological investigation. Hepatology 1989, 9:856-860.
44. Berhane T., Vetrhus M., Hausken T., et al. Pain attacks in non-complicated and complicated gallstone disease have a characteristic pattern and are accompanied by dyspepsia in most patients: the results of a prospective study. Scand J Gastroenterol 2006, 41(1):93-101.
45. Friedman G.D., Raviola C.A., Fireman B. Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol 1989, 42(2):127-136.
46. Hou R., Goldberg A.C. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 2009, 38(1):79-97.
47. Wang H.H., Portincasa P., Mendez-Sanchez N., et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008, 134:2101-2110.
48. Gibney E.J. Asymptomatic gallstones. Br J Surg 1990, 77(4):368-372.
49. Festi D., Sottili S., Colecchia A., et al. Clinical manifestations of gallstone disease: evidence from the multicenter Italian study on cholelithiasis (MICOL). Hepatology 1999, 30(4):839-846.
50. Thistle J.L., Cleary P.A., Lachin J.M., et al. The natural history of cholelithiasis: the National Cooperative Gallstone Study. Ann Intern Med 1984, 101(2):171-175.
51. Venneman N.G., Renooij W., Rehfeld J.F., et al. Small gallstones, preserved gallbladder motility, and fast crystallization are associated with pancreatitis. Hepatology 2005, 41(4):738-746.
52. Venneman N.G., Buskens E., Besselink M.G., et al. Small gallstones are associated with increased risk of acute pancreatitis: potential benefits of prophylactic cholecystectomy?. Am J Gastroenterol 2005, 100(11):2540-2550.
53. Lee S.P., Nicholls J.F., Park H.Z. Biliary sludge as a cause of acute pancreatitis. N Engl J Med 1992, 326(9):589-593.
54. Paumgartner G., Carr-Locke D.L., Dubois F., et al. Strategies in the treatment of gallstone disease. Working team report. Gastroenterol Int 1993, 6:65-75.
55. Brugge W.R. The silent gallstone. Gallbladder and biliary tract diseases 2000, 447-453. Marcel Dekker, Inc, New York, Basel. N.H. Afdhal (Ed.).
56. Tait N., Little J.M. The treatment of gall stones. BMJ 1995, 311(6997):99-105.
57. Hofmann A.F., Amelsberg A., Vansonnenberg E. Pathogenesis and treatment of gallstones. N Engl J Med 1993, 328(25):1854-1855.
58. Johnston D.E., Kaplan M.M. Pathogenesis and treatment of gallstones. N Engl J Med 1993, 328:412-421.
59. Thistle J.L., May G.R., Bender C.E., et al. Dissolution of cholesterol gallbladder stones by methyl tert-butyl ether administered by percutaneous transhepatic catheter. N Engl J Med 1989, 320:633-639.
60. Sauerbruch T., Delius M., Paumgartner G., et al. Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med 1986, 314(13):818-822.
61. Elta G.H., Barnett J.L. Meperidine need not be proscribed during sphincter of Oddi manometry. Gastrointest Endosc 1994, 40(1):7-9.
62. Kumar A., Deed J.S., Bhasin B., et al. Comparison of the effect of diclofenac with hyoscine-N-butylbromide in the symptomatic treatment of acute biliary colic. ANZ J Surg 2004, 74(7):573-576.
63. Al-Waili N., Saloom K.Y. The analgesic effect of intravenous tenoxicam in symptomatic treatment of biliary colic: a comparison with hyoscine N-butylbromide. Eur J Med Res 1998, 3(10):475-479.
64. Akriviadis E.A., Hatzigavriel M., Kapnias D., et al. Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study. Gastroenterology 1997, 113(1):225-231.
65. Goldman G., Kahn P.J., Alon R., et al. Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor. Dig Dis Sci 1989, 34(6):809-811.
66. Gurusamy K.S., Samraj K. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Cochrane Database Syst Rev 2006, (4). CD005440.
67. Gracie W.A., Ransohoff D.F. The natural history of silent gallstones: the " innocent gallstone" is not a myth. N Engl J Med 1982, 307:798-800.
68. Friedman G.D. Natural history of asymptomatic and symptomatic gallstones. Am J Surg 1993, 165(4):399-404.
69. Tint G.S., Salen G., Colalillo A., et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 1982, 97(3):351-356.
70. Meredith T.J., Williams G.V., Maton P.N., et al. Retrospective comparison of 'Cheno' and 'Urso' in the medical treatment of gallstones. Gut 1982, 23(5):382-389.
71. Tomida S., Abei M., Yamaguchi T., et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 1999, 30:6-13.
72. Venneman N.G., Besselink M.G., Keulemans Y.C., et al. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology 2006, 43(6):1276-1283.
73. Paumgartner G., Pauletzki J., Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl 1994, 204:27-31.
74. Rewbridge A.G. The disappearance of gallstone shadows following the prolonged administration of bile acids. Surgery 1937, 1:395-400.
75. Schiff M. Il coleinato di soda nella cura dei calcoli biliari. L'imparziale 1873, 13:97-98. [in Italian].
76. Dabney W.C. The use of choleate of soda to prevent the formation of gallstones. Am J Med Sci 1876, 71:410.
77. Danzinger R.G., Hofmann A.F., Schoenfield L.J. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 1972, 286:1-8.
78. Makino I., Shinozaki K., Yoshino K., et al. Nippon Shokakibyo Gakkai Zasshi 1975, 72:690-702. [in Japanese].
79. Kupfer R.M., Maudgal D.P., Northfield T.C. Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet. Dig Dis Sci 1982, 27(11):1025-1029.
80. Lanzini A., Facchinetti D., Northfield T.C. Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration. Gastroenterology 1988, 95(4):1029-1035.
81. van Erpecum K.J., Portincasa P., Stolk M.F., et al. Effects of bile salt and phospholipid hydrophobicity on lithogenicity of human gallbladder bile. Eur J Clin Invest 1994, 24:744-750.
82. van Erpecum K.J., Portincasa P., Gadellaa M., et al. Effects of bile salt hydrophobicity on nucleation behaviour of cholesterol crystals in model bile. Eur J Clin Invest 1996, 26:602-608.
83. Portincasa P., van Erpecum K.J., Jansen A., et al. Behavior of various cholesterol crystals in bile from gallstone patients. Hepatology 1996, 23:738-748.
84. Moschetta A., vanBerge-Henegouwen G.P., Portincasa P., et al. Cholesterol crystallization in model biles. Effects of bile salt and phospholipid species composition. J Lipid Res 2001, 42(8):1273-1281.
85. Hardison W.G., Grundy S.M. Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology 1984, 87(1):130-135.
86. Uchida K., Akiyoshi T., Igimi H., et al. Differential effects of ursodeoxycholic acid and ursocholic acid on the formation of biliary cholesterol crystals in mice. Lipids 1991, 26:526-530.
87. Wang D.Q., Tazuma S., Cohen D.E., et al. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol 2003, 285(3):G494-G502.
88. van de Heijning B.J., van de Meeberg P., Portincasa P., et al. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Dig Dis Sci 1999, 44:190-196.
89. Guarino M.P., Cong P., Cicala M., et al. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 2007, 56(6):815-820.
90. Portincasa P., Di Ciaula A., vanBerge-Henegouwen G.P. Smooth muscle function and dysfunction in gallbladder disease. Curr Gastroenterol Rep 2004, 6(2):151-162.
91. Xiao Z.L., Rho A.K., Biancani P., et al. Effects of bile acids on the muscle functions of guinea pig gallbladder. Am J Physiol Gastrointest Liver Physiol 2002, 283(1):G87-G94.
92. Stolk M.F., van de Heijning B.J., van Erpecum K.J., et al. Effect of bile salts on in vitro gallbladder motility: preliminary study. Ital J Gastroenterol Hepatol 1996, 28:105-110.
93. Xiao Z.L., Biancani P., Carey M.C., et al. Hydrophilic but not hydrophobic bile acids prevent gallbladder muscle dysfunction in acute cholecystitis. Hepatology 2003, 37(6):1442-1450.
94. Maurer K.J., Rao V.P., Ge Z., et al. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology 2007, 133(4):1304-1315.
95. Pauletzki J.G., Althaus R., Holl J., et al. Gallbladder emptying and gallstone formation: a prospective study on gallstone recurrence. Gastroenterology 1996, 111:765-771.
96. Portincasa P., van Erpecum K.J., van de Meeberg P.C., et al. Apolipoprotein (Apo) E4 genotype and galbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Hepatology 1996, 24:580-587.
97. Venneman N.G., vanBerge-Henegouwen G.P., Portincasa P., et al. Absence of apolipoprotein E4 genotype, good gallbladder motility and presence of solitary stones delay rather than prevent gallstone recurrence after extracorporeal shock wave lithotripsy. J Hepatol 2001, 35(1):10-16.
98. Festi D., Frabboni R., Bazzoli F., et al. Gallbladder motility in cholesterol gallstone disease. Effect of ursodeoxycholic acid administration and gallstone dissolution. Gastroenterology 1990, 99:1779-1785.
99. Sackmann M., Eder H., Spengler U., et al. Gallbladder emptying is an important factor in fragment disappearance after shock wave lithotripsy. J Hepatol 1993, 17:62-66.
100. Leopold G.R., Amberg J., Gosink B.B., et al. Gray scale ultrasonic cholecystography: a comparison with conventional radiographic techniques. Radiology 1976, 121(2):445-448.
101. Portincasa P., Di Ciaula A., Palmieri V.O., et al. Sonographic evaluation of gallstone burden in humans. Ital J Gastroenterol Hepatol 1994, 26(3):141-144.
102. Everson G.T., Braverman D.Z., Johnson M.L., et al. A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology 1980, 79:40-46.
103. Portincasa P., Moschetta A., Colecchia A., et al. Measurement of gallbladder motor function by ultrasonography: towards for standardization. Dig Liver Dis 2003, 35(Suppl 3):S56-S61. (già Ital J Gastroenterol Hepatol).
104. Portincasa P., Di Ciaula A., Baldassarre G., et al. Gallbladder motor function in gallstone patients: sonographic and in vitro studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation. J Hepatol 1994, 21:430-440.
105. Portincasa P., Moschetta A., Di Ciaula A., et al. Pathophysiology of cholesterol gallstone disease. Biliary lithiasis. Basic science, current diagnosis and management 2008, 19-49. Springer Italia S.r.l, Milano (Italy). G. Borzellino, C. Cordiano (Eds.).
106. Pereira S.P., Veysey M.J., Kennedy C., et al. Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse. Dig Dis Sci 1997, 42(8):1775-1782.
107. Pereira S.P., Hussaini S.H., Kennedy C., et al. Gallbladder stone recurrence after medical treatment. Do gallstones recur true to type?. Dig Dis Sci 1995, 40:2568-2575.
108. Senior J.R., Johnson M.F., DeTurck D.M., et al. In vivo kinetics of radiolucent gallstone dissolution by oral dihydroxy bile acids. Gastroenterology 1990, 99(1):243-251.
109. Jazrawi R.P., Pigozzi M.G., Galatola G., et al. Optimum bile acid treatment for rapid gall stone dissolution. Gut 1992, 33:381-386.
110. Paumgartner G. Therapeutic options and choice of appropriate treatment. Bile acids-cholestasis-gallstones. Advances in basic and clinical bile acid research 1996, Kluwer Academic Publishers, Dordrecht (The Netherlands), p. 205-10.
111. Bateson M.C., Bouchier I.A., Trash D.B., et al. Calcification of radiolucent gall stone during treatment with ursodeoxycholic acid. Br Med J (Clin Res Ed) 1981, 283(6292):645-646.
112. Bazzoli F., Festi D., Mazzella G., et al. Acquired gallstone opacification during cholelitholytic treatment with chenodeoxyholic, ursodeoxycholic, and tauroursodeoxycholic acids. Am J Gastroenterol 1995, 90(6):978-981.
113. Lanzini A., Jazrawi R.P., Kupfer R.M., et al. Gallstone recurrence after medical dissolution. An overestimated threat?. J Hepatol 1986, 3:241-246.
114. Rabenstein T., Radespiel-Troger M., Hopfner L., et al. Ten years experience with piezoelectric extracorporeal shockwave lithotripsy of gallbladder stones. Eur J Gastroenterol Hepatol 2005, 17(6):629-639.
115. Sackmann M., Ippisch E., Sauerbruch T., et al. Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology 1990, 98:392-396.
116. Villanova N., Bazzoli F., Taroni F., et al. Gallstone recurrence after successful oral bile acid treatment: a 12 year follow-up study and evaluation of long term postdissolution treatment. Gastroenterology 1989, 97:726-731.
117. Petroni M.L., Jazrawi R.P., Pazzi P., et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 2000, 12(6):695-700.
118. Petroni M.L., Jazrawi R.P., Lanzini A., et al. Repeated bile acid therapy for the long-term management of cholesterol gallstones. J Hepatol 1996, 25:719-724.
119. O'Leary D.P., Johnson A.G. Future directions for conservative treatment of gallbladder calculi. Br J Surg 1993, 80(2):143-147.
120. Gilat T., Konikoff F. Pregnancy and the biliary tract. Can J Gastroenterol 2000, 14(Suppl D):55D-59D.
121. Sugerman H.J., Brewer W.H., Shiffman M.L., et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg 1995, 169(1):91-96.
122. Lammert F., Neubrand M.W., Bittner R., et al. Z Gastroenterol 2007, 45(9):971-1001. [in German].
123. Portincasa P., Di Ciaula A., Wang H.H., et al. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr Med Chem 2009, 16(12):1531-1542.
124. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292(5519):1160-1164.
125. Kallien G., Lange K., Stange E.F., et al. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology 1999, 30(1):14-20.
126. Duane W.C., Hunninghake D.B., Freeman M.L., et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988, 8:1147-1150.
127. Loria P., Bertolotti M., Cassinadri M.T., et al. Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology 1994, 19:882-888.
128. Hanson D.S., Duane W.C. Effects of lovastatin and chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects. J Lipid Res 1994, 35(8):1462-1468.
129. Saunders K.D., Cates J.A., Abedin M.Z., et al. Lovastatin and gallstone dissolution: a preliminary study. Surgery 1993, 113:28-35.
130. Smit J.W., van Erpecum K.J., Renooij W., et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995, 21(6):1523-1529.
131. Tazuma S., Hatsushika S., Aihara N., et al. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion 1992, 51:179-184.
132. Abedin M.Z., Narins S.C., Park E.H., et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci 2002, 47(10):2192-2210.
133. Davis K.G., Wertin T.M., Schriver J.P. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes Surg 2003, 13(6):865-868.
134. Chapman B.A., Burt M.J., Chisholm R.J., et al. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci 1998, 43(2):349-353.
135. Porsch-Ozcurumez M., Hardt P.D., Schnell-Kretschmer H., et al. Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur J Clin Pharmacol 2001, 56(12):873-879.
136. Smith J.L., Roach P.D., Wittenberg L.N., et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000, 15(8):871-879.
137. Wilson I.R., Hurrell M.A., Pattinson N.R., et al. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics. J Gastroenterol Hepatol 1994, 9(5):447-451.
138. Miettinen T.E., Kiviluoto T., Taavitsainen M., et al. Cholesterol metabolism and serum and biliary noncholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments. Hepatology 1998, 27(3):649-655.
139. Sharma B.C., Agarwal D.K., Baijal S.S., et al. Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol. J Clin Gastroenterol 1997, 25(2):433-436.
140. Caroli-Bosc F.X., Le G.P., Pugliese P., et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001, 46(3):540-544.
141. Gonzalez-Perez A., Garcia-Rodriguez L.A. Gallbladder disease in the general population: association with cardiovascular morbidity and therapy. Pharmacoepidemiol Drug Saf 2007, 16(5):524-531.
142. Tsai C.J., Leitzmann M.F., Willett W.C., et al. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009, 136(5):1593-1600.
143. Bodmer M., Brauchli Y.B., Krahenbuhl S., et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009, 302(18):2001-2007.
144. Wang D.Q. Regulation of intestinal cholesterol absorption. Annu Rev Physiol 2007, 69:221-248.
145. Davis H.R., Zhu L.J., Hoos L.M., et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004, 279(32):33586-33592.
146. Altmann S.W., Davis H.R., Zhu L., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
147. Davies J.P., Scott C., Oishi K., et al. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005, 280(13):12710-12720.
148. Ge L., Wang J., Qi W., et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008, 7(6):508-519.
149. Valasek M.A., Repa J.J., Quan G., et al. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008, (4):G813-G822.
150. Davis H.R., Veltri E.P. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007, 14(3):99-108.
151. Zuniga S., Molina H., Azocar L., et al. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008, 28(7):935-947.
152. Wang D.Q., Tazuma S. Effect of beta-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res 2002, 43(11):1960-1968.
153. Mathur A., Walker J.J., Al-Azzawi H.H., et al. Ezetimibe ameliorates cholecystosteatosis. Surgery 2007, 142(2):228-233.
154. Mangelsdorf D.J., Thummel C., Beato M., et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83(6):835-839.
155. Janowski B.A., Willy P.J., Devi T.R., et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383(6602):728-731.
156. Parks D.J., Blanchard S.G., Bledsoe R.K., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284(5418):1365-1368.
157. Makishima M., Okamoto A.Y., Repa J.J., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284(5418):1362-1365.
158. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 2002, 8(11):1243-1248.
159. Kalaany N.Y., Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006, 68:159-191.
160. Modica S., Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?. FEBS Lett 2006, 580(23):5492-5499.
161. Moschetta A., Bookout A.L., Mangelsdorf D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 2004, 10(12):1352-1358.
162. Liu Y., Binz J., Numerick M.J., et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003, 112(11):1678-1687.
163. Uppal H., Zhai Y., Gangopadhyay A., et al. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology 2008, 47(4):1331-1342.
164. Keus F., de Jong J.A., Gooszen H.G., et al. Small-incision versus open cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev 2006, (4). CD004788.
165. Keus F., de Jong J.A., Gooszen H.G., et al. Laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev 2006, (4). CD006231.
166. Keus F., de Jong J.A., Gooszen H.G., et al. Laparoscopic versus small-incision cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev 2006, (4). CD006229.
167. Pokorny W.J., Saleem M., O'Gorman R.B., et al. Cholelithiasis and cholecystitis in childhood. Am J Surg 1984, 148(6):742-744.
168. Amaral J.F., Thompson W.R. Gallbladder disease in the morbidly obese. Am J Surg 1985, 149(4):551-557.
169. Sleisenger M.H., Fordtran J.S. Gastrointestinal disease: pathophysiology, diagnosis, management 2006, WB Saunders, Philadelphia. 8th edition.
170. Lowenfels A.B., Walker A.M., Althaus D.P., et al. Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol 1989, 18:50-54.
171. Randi G., Franceschi S., La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006, 118(7):1591-1602.
172. Ashur H., Siegal B., Oland Y., et al. Calcified ballbladder (porcelain gallbladder). Arch Surg 1978, 113(5):594-596.
173. Lowenfels A.B., Lindstrom C.G., Conway M.J., et al. Gallstones and risk of gallbladder cancer. J Natl Cancer Inst 1985, 75(1):77-80.
174. Bonatsos G., Birbas K., Toutouzas K., et al. Laparoscopic cholecystectomy in adults with sickle cell disease. Surg Endosc 2001, 15(8):816-819.
175. Wang D.Q.H., Carey M.C. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing system. J Lipid Res 1996, 37:606-630.